Product Images Pregabalin
View Photos of Packaging, Labels & Appearance
- MM2 - Pregabalin 150mg 70518 3345 01
- Remedy_Label - Remedy Label
- equation - pregabain gault equation
- fig-01 - pregabalin figure 01
- fig-02 - pregabalin figure 02
- fig-03 - pregabalin figure 03
- fig-04 - pregabalin figure 04
- fig-05 - pregabalin figure 05
- fig-06 - pregabalin figure 06
- fig-07 - pregabalin figure 07
- fig-09 - pregabalin figure 09
- fig-10 - pregabalin figure 10
- fig-11 - pregabalin figure 11
- fig-12 - pregabalin figure 12
- str - pregabalin structure
Product Label Images
The following 15 images provide visual information about the product associated with Pregabalin NDC 70518-3345 by Remedyrepack Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
MM2 - Pregabalin 150mg 70518 3345 01
This text is a label for Pregabalin medication manufactured by Novadoz Pharmaceuticals LLC in New Jersey with an NDC code of 70518-3345-01 and a strength of 150mg. The medication comes in a bottle with 90 capsules and should be kept out of the reach of children. The lot number and expiration date are not mentioned. The package insert should be referred to for usage instruction, and the medication should be stored between 20-26°C (63-77°F). It has been repackaged by RemedyRepack Inc in Indiana, PA for Rx only.*
Remedy_Label - Remedy Label
Pregabalin is a medication sold with NDC# 70518-3345-00 that is manufactured in 150 mg capsules by Novadoz Pharmaceuticals LLC, Paterson, New Jersey, USA. The lot number and expiration date are not readable in the given text. The packing includes 60 capsules that come with package inserts. The medication is repackaged by RemedyRepack Inc., Indiana, PA. It is advised to store the medication within 20-26°C (63-77°F), with excursions permitted to 15-30°C (59-86°F) [See USP]. Keep out of reach of children.*
equation - pregabain gault equation
fig-01 - pregabalin figure 01
This text provides the percentage of patients who improved in relation to different dosages of Pregabalin and a placebo. The improvement is measured in pain reduction from a baseline value. The text includes a graph showing the percentage of patients improved at different levels for each dosage of Pregabalin and the placebo.*
fig-02 - pregabalin figure 02
The data shows the percentage of patients who improved after taking Pregabalin 100 mg three times a day versus a placebo. The graph displays the percentage of pain improvement from baseline, with the Pregabalin group showing significant improvement compared to the placebo group.*
fig-03 - pregabalin figure 03
The text represents a chart showing the percent of improvement in pain for patients using Pregabalin at different dosages and a placebo. The chart shows a range of percent improvement from 0 to 90. There is no other information available to provide a meaningful description.*
fig-04 - pregabalin figure 04
The text presents a graph that shows the percentage of patients who improved while taking Pregabalin 200mg three times a day, Pregabalin 100mg three times a day, and Placebo. The percentages are organized according to the percentage of improvement in pain from the baseline, ranging from >10 to >90%.*
fig-05 - pregabalin figure 05
This appears to be a chart showing the percentage of patients who experienced improvement in pain based on different dosages of Pregabalin and a placebo. The chart displays percentages ranging from 10% to 100% with the corresponding dosage and treatment displayed next to each percentage. The chart provides information on the effectiveness of different dosages of Pregabalin in treating pain.*
fig-06 - pregabalin figure 06
The text is presenting responder rates (%) of different studies (E1, E3) testing various dosages of an unspecified medication. The medication doses tested were 50mg/day, 150mg/day, 300mg/day, and 600mg/day. The responder rates ranged from 9-51% and were statistically significant. No further information or context is available.*
fig-07 - pregabalin figure 07
This appears to be a graph or chart with some statistical values indicating significant p-values when comparing different doses. However, without more context or information it is not possible to provide a more accurate description.*
fig-09 - pregabalin figure 09
This appears to be a graph depicting the percent of patients who have improved over time in response to different doses of pregabalin versus a placebo. The x-axis indicates the percentage of pain improvement from baseline, while the y-axis lists the different doses of pregabalin and the placebo. Some of the doses include 300 mg, 450 mg, and 600 mg per day. However, without additional context, it is difficult to provide more specific information.*
fig-10 - pregabalin figure 10
fig-11 - pregabalin figure 11
The text is a graph representing the percentage of subjects who showed improvement from baseline to week 12 for the drug Pregabalin and Placebo. The horizontal axis represents the percentage range from 0 to 100, and the vertical axis shows the percentage of subjects improved. The graph suggests that Pregabalin had a higher percentage of subjects who improved compared to Placebo.*
fig-12 - pregabalin figure 12
This is a graph representing the percentage of subjects who experienced improvement from baseline to week 16 using Pregabalin and Placebo. The top axis represents the percentage of improvement, from 10% to 100%, and the side axis represents the number of subjects.*
str - pregabalin structure
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.
